The trial, ACT-OA, is a phase II, randomized, double-blind, placebo-controlled trial including 90 patients. It aims to evaluate the efficacy and safety of Cytori Cell Therapy — the company’s autologous adipose derived therapy.
The patient was treated by Peter Hanson, MD, medical director of orthopedic surgery at Sharp Grossmont Hospital in San Diego.
More articles on devices:
Medtronic’s VERTEX Reconstruction System receives FDA approval for expanded indications
Sonoma Orthopedic Products receives FDA clearance for FibuLock Nail
Argus raises Integra Lifesciences’ price target to $61
